Runx1 Antibody

What is RUNX1 and why is it important in research?

RUNX1 (also known as AML1) is a 50-kDa transcription factor primarily expressed in hematopoietic cells including myeloid, T, and B cells, but not erythroid cells. It can be detected in nearly all non-hematopoietic tissues except the brain and heart. RUNX1 plays crucial roles in T cell development, including the CD4-CD8- double negative to CD4+CD8+ double positive transition and commitment to the CD4 lineage. It's also implicated in Th2 differentiation and immune homeostasis through direct interaction with Foxp3 in CD4+CD25+ regulatory T cells. The AML1 gene encoding RUNX1 is a frequent target of translocations in acute myeloid leukemia, making it a significant focus in cancer research .

How many RUNX1 isoforms exist, and which antibodies can detect them?

In humans, alternative splicing results in eleven different RUNX1 isoforms, while mice express five isoforms. Isoform 4 (AML1-C) is the most highly expressed variant in mouse hematopoietic cells. When selecting antibodies, researchers should consider isoform specificity. For example, the RXDMC monoclonal antibody recognizes isoform 4 in mouse and all human isoforms except AML-1FA, AML-1FB, and AML-1FC . For studies focused on specific isoforms like RUNX1C, specialized antibodies such as those targeting the unique 16 amino acid N-terminus of RUNX1C may be required to differentiate between isoforms B and C .

What are the recommended applications for RUNX1 antibodies?

RUNX1 antibodies can be employed across multiple experimental approaches depending on research needs:

• Intracellular flow cytometry: Validated for analyzing RUNX1 expression in cell populations

• Immunohistochemistry (IHC-P): For detection in paraffin-embedded tissues

• Western blotting: For protein expression analysis

• Immunoprecipitation (IP): For protein interaction studies

• Chromatin immunoprecipitation (ChIP): For studying RUNX1 binding to DNA targets

• Immunofluorescence: For cellular localization studies

• CUT&RUN-seq: For high-resolution chromatin profiling

Each application requires specific optimization parameters, including antibody dilution, incubation time, and sample preparation methods.

How should RUNX1 antibodies be optimized for flow cytometry?

For optimal intracellular flow cytometry results with RUNX1 antibodies, careful titration is essential. The RXDMC antibody can be used at ≤1 μg per test, where a test is defined as the amount of antibody that will stain a cell sample in a final volume of 100 μL. Cell numbers can range from 10^5 to 10^8 cells/test, though this should be empirically determined for each experiment .

For intracellular staining, specialized buffer sets such as the Foxp3/Transcription Factor Staining Buffer Set are recommended to adequately permeabilize cells and expose nuclear transcription factors like RUNX1. Researchers should include appropriate isotype controls and validate staining patterns against known RUNX1-positive and negative cell populations. For analysis of specific isoforms, antibodies with documented specificity for particular RUNX1 variants should be selected .

What are the critical considerations for detecting RUNX1 in immunohistochemistry?

For successful immunohistochemical detection of RUNX1, proper antigen retrieval is crucial. Heat-mediated antigen retrieval with Tris-EDTA buffer (pH 9.0) for approximately 20 minutes has been validated for RUNX1 detection in paraffin-embedded tissues. When using antibodies like ab240639, optimal dilutions (e.g., 1/2000 or 0.25 μg/ml) should be determined empirically .

Proper controls are essential, including secondary antibody-only controls and positive control tissues with known RUNX1 expression patterns. Nuclear staining is the expected pattern for RUNX1, though weak cytoplasmic staining may also be observed in some cell types. Counterstaining with hematoxylin provides contextual cellular information. For automated systems, protocols have been validated on platforms such as the Leica Biosystems BOND® RX instrument with 15-minute primary antibody incubation times .

How can researchers differentiate between RUNX1 isoforms in experimental settings?

Differentiating between RUNX1 isoforms requires carefully selected antibodies targeting isoform-specific epitopes. For distinguishing RUNX1C from other isoforms, antibodies targeting the unique 32 additional amino acids at the N-terminus of RUNX1C (compared to RUNX1B) can be used. Validation of isoform specificity can be performed in cell lines lacking endogenous RUNX1 (such as HeLa cells) transfected with specific RUNX1 isoforms .

In experimental designs requiring isoform discrimination, researchers should:

• Validate antibody specificity using Western blotting against recombinant isoforms

• Consider using isoform-specific primers for qPCR to correlate protein with transcript levels

• When possible, employ cells with known isoform expression patterns as positive controls

• For complex samples, consider combining immunoprecipitation with Western blotting using isoform-specific antibodies

How can RUNX1 antibodies be applied in chromatin immunoprecipitation (ChIP) studies?

For effective ChIP analysis of RUNX1 binding sites, researchers should consider the following methodological approach:

• Cell preparation: Use appropriate cell numbers (typically 1-5×10^6 cells per immunoprecipitation) and crosslink with formaldehyde (typically 1% for 10 minutes)

• Sonication: Optimize sonication conditions to achieve chromatin fragments of 200-500bp

• Antibody selection: Choose antibodies validated for ChIP applications, such as those recognizing all RUNX1 isoforms or isoform-specific antibodies depending on research questions

• Controls: Include IgG controls and positive control regions known to bind RUNX1

• Analysis: Employ qPCR primers targeting consensus RUNX1 binding sites (e.g., regions in P1 and P2 promoters)

ChIP studies have successfully demonstrated that both RUNX1B and RUNX1C isoforms bind to P1 and P2 promoters, with RUNX1C showing particular affinity for these regions. When designing ChIP experiments, researchers should consider that different RUNX1 isoforms may have distinct binding preferences and functional outcomes .

How do different RUNX1 isoforms affect downstream gene regulation?

RUNX1 isoforms B and C regulate target genes differentially, with significant implications for cellular function. When investigating these differences, researchers should consider the following experimental approaches:

• Overexpression studies: Transfect cells (e.g., HEL or HeLa cells) with varying concentrations of RUNX1B or RUNX1C expression vectors

• Protein analysis: Use Western blotting with appropriate antibodies to detect expression of RUNX1 isoforms and downstream targets

• Transcript analysis: Employ qPCR to measure expression changes in target genes

• Normalization: Use stable reference genes such as GAPDH

Research has shown that in HEL cells, RUNX1B overexpression decreases RUNX1C and RUNX1A expression, while RUNX1C increases RUNX1B and RUNX1A. Target genes like MYL9, F13A1, PCTP, and PDE5A are regulated differently by these isoforms, as shown in the following expression correlation data:

This differential regulation has clinical significance, as expression patterns of RUNX1 isoforms and their targets associate with acute events in cardiovascular disease .

How can proximity ligation assays (PLA) be used to study RUNX1 protein interactions?

Proximity ligation assays offer a powerful approach to visualize and quantify protein-protein interactions involving RUNX1 in situ. For investigating RUNX1 interactions with partners such as CBFβ, researchers can employ the following methodology:

• Sample preparation: Fix cells or tissue sections with paraformaldehyde (typically 4%) and permeabilize with Triton X-100

• Primary antibodies: Apply antibodies against RUNX1 (such as C-terminal RUNX1 antibody) and the interaction partner (e.g., CBFβ)

• PLA probes: Use secondary antibodies conjugated to oligonucleotides

• Ligation and amplification: Follow manufacturer's protocols for proximity-dependent DNA ligation and rolling circle amplification

• Detection: Visualize using fluorescence microscopy with appropriate counterstains like DAPI

This technique has been successfully employed to detect endogenous RUNX1 interactions with CBFβ, providing spatial information about these interactions within cellular compartments. When comparing wild-type RUNX1 with mutant variants, PLA can reveal alterations in protein interaction networks that may contribute to disease mechanisms .

What approaches can be used to study mutant RUNX1 proteins in oncogenic contexts?

Investigating mutant RUNX1 oncoproteins requires multiple complementary approaches:

• Expression analysis: Transfect cells with tagged mutant RUNX1 constructs (e.g., HA-tagged) for expression validation

• Immunocytochemistry: Use anti-tag antibodies (anti-HA) or RUNX1-specific antibodies to visualize subcellular localization

• Interaction studies: Employ PLA to assess interactions between mutant RUNX1 and cofactors like CBFβ

• Functional assays: Measure transcriptional activity using reporter constructs containing RUNX1 binding sites

• Downstream impact: Analyze expression of RUNX1 target genes using qPCR or RNA-seq

Research has shown that different RUNX1 mutations can program alternate oncogenic pathways. When designing experiments to study these mutants, researchers should consider both the direct effects on RUNX1 function and the broader impact on cellular signaling networks. Appropriate cellular models include those with endogenous RUNX1 expression (e.g., hematopoietic cell lines) and those lacking endogenous RUNX1 (e.g., HeLa cells) for clean background in overexpression studies .

What are common issues in RUNX1 antibody applications and how can they be resolved?

When working with RUNX1 antibodies, researchers may encounter several technical challenges:

• Weak or absent signal in flow cytometry:

  • Ensure adequate permeabilization using specialized buffers for nuclear transcription factors

  • Optimize antibody concentration through careful titration

  • Verify antibody compatibility with fixation and permeabilization reagents

  • Use positive control samples with known RUNX1 expression

• High background in immunohistochemistry:

  • Optimize blocking conditions (typically 5-10% serum from the species of secondary antibody)

  • Ensure adequate washing between steps

  • Validate antibody specificity using RUNX1-negative tissues

  • Titrate primary and secondary antibodies to minimize non-specific binding

• Multiple bands in Western blotting:

  • Verify if bands correspond to known RUNX1 isoforms (ranging from approximately 48-52 kDa)

  • Consider post-translational modifications that may affect migration

  • Optimize sample preparation to minimize protein degradation

  • Use isoform-specific antibodies when targeting particular variants

How should researchers validate the specificity of RUNX1 antibodies?

Rigorous validation of RUNX1 antibodies is essential for experimental reproducibility and reliability. A comprehensive validation strategy includes:

• Positive and negative controls:

  • Use cell lines with known RUNX1 expression (e.g., HEL cells) as positive controls

  • Use RUNX1-negative cells (e.g., untransfected HeLa cells) as negative controls

• Isoform specificity testing:

  • Express recombinant RUNX1 isoforms in cells lacking endogenous RUNX1

  • Perform Western blotting to confirm antibody specificity for target isoforms

• Knockdown/knockout validation:

  • Use siRNA or CRISPR to reduce or eliminate RUNX1 expression

  • Confirm reduced antibody signal correlating with reduced RUNX1 levels

• Cross-reactivity assessment:

  • Test antibody against related proteins (e.g., RUNX2, RUNX3) to ensure specificity

  • Validate across species if performing comparative studies

What considerations are important when studying RUNX1 in clinical samples?

When applying RUNX1 antibodies to clinical specimens, researchers should address several methodological challenges:

• Sample preservation and fixation:

  • Optimize fixation protocols (typically 10% neutral buffered formalin for 24-48 hours)

  • Minimize time between sample collection and fixation to preserve protein integrity

• Antigen retrieval optimization:

  • Test multiple antigen retrieval methods (heat-mediated with Tris-EDTA buffer at pH 9.0 has proven effective)

  • Adjust retrieval duration based on tissue type and fixation conditions

• Background reduction in patient samples:

  • Include appropriate blocking steps to minimize non-specific binding

  • Consider tissue-specific autofluorescence quenching for immunofluorescence applications

• Quantification strategies:

  • Develop consistent scoring systems for RUNX1 positivity

  • Consider digital image analysis for objective quantification

  • Correlate RUNX1 expression with clinical parameters and outcomes

Research has demonstrated clinical relevance of RUNX1 expression patterns, particularly in cardiovascular disease where RUNX1C transcripts in whole blood were protective against acute events, while higher expression of RUNX1 targets F13A1 and RAB31 associated with acute events .

How can CUT&RUN-seq enhance RUNX1 chromatin binding studies?

Cleavage Under Targets and Release Using Nuclease (CUT&RUN) combined with sequencing offers significant advantages over traditional ChIP-seq for studying RUNX1 genomic occupancy:

• Methodological benefits:

  • Requires fewer cells (as few as 5,000 compared to millions for ChIP-seq)

  • Produces lower background and higher signal-to-noise ratio

  • Enables higher resolution mapping of binding sites

• Implementation for RUNX1 studies:

  • Select antibodies validated specifically for CUT&RUN applications

  • Optimize binding conditions for nuclear transcription factors like RUNX1

  • Consider isoform-specific antibodies to distinguish binding patterns of RUNX1B versus RUNX1C

• Analysis considerations:

  • Compare RUNX1 binding patterns with expression data to identify functional binding events

  • Integrate with chromatin accessibility data (ATAC-seq) to understand regulatory context

  • Analyze co-binding with RUNX1 partners like CBFβ

This technique can reveal previously unidentified RUNX1 binding sites and provide insights into isoform-specific chromatin interactions that regulate hematopoietic development and disease processes.

What new insights are emerging about RUNX1 isoform-specific functions?

Recent research has revealed important functional differences between RUNX1 isoforms:

• Autoregulatory mechanisms:

  • RUNX1B and RUNX1C bind to P1 and P2 promoters differently

  • In HeLa cells, RUNX1B decreases while RUNX1C increases P1 and P2 activities

  • In HEL cells, RUNX1B overexpression decreases RUNX1C and RUNX1A expression, while RUNX1C increases RUNX1B and RUNX1A

• Differential target gene regulation:

  • Target genes like MYL9, F13A1, PCTP, and PDE5A are regulated differently by RUNX1B and RUNX1C

  • In platelets, RUNX1B transcripts correlate negatively with RUNX1C and RUNX1A, while RUNX1C correlates positively with RUNX1A

• Clinical implications:

  • RUNX1C transcripts in whole blood are protective against acute events in cardiovascular disease patients

  • Higher expression of RUNX1 targets F13A1 and RAB31 associates with acute cardiovascular events

These findings suggest that therapeutic strategies targeting specific RUNX1 isoforms might offer more precise interventions for RUNX1-associated diseases.